Heart Failure With Anemia

Eileen O’Meara(Montreal Heart Institute), Dr Nadeau(Hôpital du Sacré-Cœur de Montréal), Anique Ducharme(Montreal Heart Institute), Dr Dion(Cegep de Thetford), Normand Racine(Montreal Heart Institute), Michel White(Montreal Heart Institute), Paul‐Eduard Neagoe(Montreal Heart Institute), Jean‐Claude Tardif(Montreal Heart Institute), Simon de Denus(Montreal Heart Institute), Dr Bergeron(Institut universitaire de cardiologie et de pneumologie de Québec), Dr Dupuis(Cegep de Thetford), Martin G. Sirois(Montreal Heart Institute), Dr Huynh(Montreal General Hospital), Karine Roy, Jean L. Rouleau(Montreal Heart Institute), François Madore(Montreal Heart Institute), Joël Lavoie(Montreal Heart Institute), Mark Liszkowski(Montreal Heart Institute), Dr Giannetti(Montreal General Hospital), Lucie Blondeau(Montreal Heart Institute)
Circulation Heart Failure
July 16, 2014
10.1161/circheartfailure.114.001100
Cited by 49

Related Papers

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k
Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis
|JAMA|2006|2k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k